Perindopril Erbumine(pur in’ doh pril)
Aceon, APO-Perindopril (CAN)
PREGNANCY CATEGORY D
Drug Classes
ACE inhibitor
Antihypertensive
Therapeutic Actions
Renin, synthesized by the kidneys, is released into the circulation where it acts on a plasma precursor to produce angiotensin I, which is converted by ACE to angiotensin II—a potent vasoconstrictor that also causes release of aldosterone from the adrenals. Perindopril blocks the conversion of angiotensin I to angiotensin II, leading to decreased BP, decreased aldosterone secretion, a small increase in serum potassium levels, and sodium and fluid loss.
Indications
Treatment of hypertension, alone or in combination with other antihypertensive
Treatment of patients with stable coronary artery disease to reduce the risk of CV mortality and nonfatal MI
NEW INDICATION: Unlabeled use: Treatment of HF
Contraindications and Cautions
Contraindicated with allergy to any ACE inhibitor, pregnancy, history of ACE inhibitors–associated angioedema.
Use cautiously with impaired renal function, HF, salt or volume depletion, lactation.
Available Forms
Tablets—2, 4, 8 mg
Dosages
Adults
Hypertension: 4 mg PO daily; may be titrated to a maximum of 16 mg/day.
CV disease: 4 mg/day PO for 2 wk; increase to a maintenance dose of 8 mg/day PO.
Pediatric patients
Safety and efficacy not established.
Geriatric patients
Maximum daily dosage should not exceed 8 mg/day.
Geriatric patients older than 70 yr with stable CV disease
2 mg/day PO for first wk; increase to 4 mg/day PO for second wk. Maintenance dose is 8 mg/day PO.
Patients with renal impairment
For CrCl greater than 30 mL/min, give initial dose of 2 mg/day PO. Maximum dose, 8 mg/day. For CrCl of 30 mL/min or less, do not administer drug.
